Emerging Atopic Dermatitis Treatments:

Slides:

Advertisements

Similar presentations

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Advertisements

Moderate-to-Severe Asthma Management

Systemic Lupus Erythematosus

Clinical Trials in IBD.

Psoriatic Arthritis.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

T-Cell Exhaustion: Can We Overcome It in Cancer?

Advances in Managing Inhibitors in Patients With Hemophilia A

Essential Updates in Atopic Dermatitis:

Clinical Developments in Inflammatory Arthritis 2017

Updates on Emerging GLP-1 Receptor Agonists

Progression After Cancer Immunotherapy in Advanced NSCLC

From Conference to Practice: Big Data in Psoriasis

Improving Acne Outcomes

Atopic Dermatitis Treatment Landscape

Updates in Management of Atopic Dermatitis From Real Patient Cases

Atopic Dermatitis Treatment Landscape

Program Goals. Program Goals What is Atopic Dermatitis?

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Therapeutic Strategies in the Management of Mild-to-Moderate Atopic Dermatitis.

The Resurgence of Topical Treatments Across a Spectrum of Psoriasis

Chronic Idiopathic Urticaria

Addressing Disease Burden in Asthma

Expert Tips for Tackling Atopic Dermatitis in Pediatric Practice

Asthma and Atopic Comorbidities

Optimizing Management of Advanced Bladder Cancer

Translating Atopic Dermatitis

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Next-Gen Psoriasis Therapies:

Hyperhidrosis Is Burdensome!

Gene Therapy: Past, Present, and Future

Atopic Dermatitis. Introduction to a Clinical Course On New Developments In Atopic Dermatitis.

Tackling Atopic Dermatitis

Ask the Experts.

Immunotherapy for cSCC

The JAK-STAT Pathway and Graft-vs-Host Disease

Perspectives on the Impact of Inflammation in OA

New Recommendations on How to Stage Hidradenitis Suppurativa

New Data on Emerging Treatments for Psoriasis

When Is Biologic Therapy Appropriate for HS?

The Evolving Treatment Landscape in Atopic Dermatitis

Current and Emerging Strategies for Management of Moderate-to-Severe Atopic Dermatitis.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.

Parkinson Disease Psychosis

Advances in Rheumatoid Arthritis Management

Immune Checkpoint Inhibitors in Lung Cancer

Understanding and Addressing the Needs of Patients With AD

Advances in Severe Asthma Management

Guide to Atopic Dermatitis

Atopic Dermatitis in the Pediatric Practice

Expanding the Horizons in Hereditary Angioedema

Patient Questions and Expert Answers in Psoriasis:

Optimizing Joint Health in Hemophilia

Update on the Management of Atopic Dermatitis

Novel Concepts in the Management of RCC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

From Adjuvant to Metastatic in Melanoma

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Pathophysiologic Targets of Allergic Asthma

Behçet Syndrome (BS) Overview

Immune Checkpoint Inhibitors in Lung Cancer

You Don't Know JAK in IBD.

Presentation transcript:

Emerging Atopic Dermatitis Treatments:

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Atopic Dermatitis

Hypotheses of Atopic Dermatitis

Atopic Dermatitis and Immune Dysfunction

Skin Barrier Dysfunction

Immune System Dysfunction

Crisaborole Topical PDE4 Inhibitor

Crisaborole Topical PDE4 Inhibitor (cont)

Patient Education

Apremilast Oral PDE4 Inhibitor

Dupilumab IL-4 Receptor α Inhibitor

Dupilumab IL-4/IL-13 Inhibitor

Dupilumab IL-4/IL-13 Inhibitor

Dupilumab Pediatric Studies

IL-13 Inhibitors Lebrikizumab and Tralokinumab

Lebrikizumab and Tralokinumab

Nemolizumab IL-31 Receptor Inhibitor

Nemolizumab

JAK Inhibitors Baricitinib and Tofacitinib

JAK Inhibitors

Patient-Centric Management of AD

The AD Tool Kit

Concluding Remarks

Abbreviations